Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H19F3N4O3 |
| Molecular Weight | 456.4172 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC(F)=CC=C1C2=NC(NC(CO)CO)=NC3=C2C=CC(=O)N3C4=C(F)C=CC=C4F
InChI
InChIKey=ORVNHOYNEHYKJG-UHFFFAOYSA-N
InChI=1S/C23H19F3N4O3/c1-12-9-13(24)5-6-15(12)20-16-7-8-19(33)30(21-17(25)3-2-4-18(21)26)22(16)29-23(28-20)27-14(10-31)11-32/h2-9,14,31-32H,10-11H2,1H3,(H,27,28,29)
| Molecular Formula | C23H19F3N4O3 |
| Molecular Weight | 456.4172 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Dilmapimod is a potent p38 mitogen-activated protein kinase (MAPK) inhibitor. It was investigated for its anti-inflammatory effect in non-head injury trauma patients at risk for developing acute respiratory distress syndrome. IL-1β was identified as a gene regulated by dilmapimod that could influence c-reactive protein levels. Dilmapimod had been in phase III clinical trials by GlaxoSmithKline for the treatment of rheumatoid arthritis, neuropathic pain, coronary artery disease (CAD) and chronic obstructive pulmonary disease (COPD). However, these studies were discontinued.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL260 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28004376 |
50.0 µM [IC50] |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21576029
15 mg per day for two weeks
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:07:03 GMT 2025
by
admin
on
Mon Mar 31 18:07:03 GMT 2025
|
| Record UNII |
Q3238VQW0N
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C2149
Created by
admin on Mon Mar 31 18:07:03 GMT 2025 , Edited by admin on Mon Mar 31 18:07:03 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
UU-45
Created by
admin on Mon Mar 31 18:07:03 GMT 2025 , Edited by admin on Mon Mar 31 18:07:03 GMT 2025
|
PRIMARY | |||
|
DB12140
Created by
admin on Mon Mar 31 18:07:03 GMT 2025 , Edited by admin on Mon Mar 31 18:07:03 GMT 2025
|
PRIMARY | |||
|
DTXSID101318338
Created by
admin on Mon Mar 31 18:07:03 GMT 2025 , Edited by admin on Mon Mar 31 18:07:03 GMT 2025
|
PRIMARY | |||
|
444606-18-2
Created by
admin on Mon Mar 31 18:07:03 GMT 2025 , Edited by admin on Mon Mar 31 18:07:03 GMT 2025
|
PRIMARY | |||
|
300000034206
Created by
admin on Mon Mar 31 18:07:03 GMT 2025 , Edited by admin on Mon Mar 31 18:07:03 GMT 2025
|
PRIMARY | |||
|
9119
Created by
admin on Mon Mar 31 18:07:03 GMT 2025 , Edited by admin on Mon Mar 31 18:07:03 GMT 2025
|
PRIMARY | |||
|
Q3238VQW0N
Created by
admin on Mon Mar 31 18:07:03 GMT 2025 , Edited by admin on Mon Mar 31 18:07:03 GMT 2025
|
PRIMARY | |||
|
CHEMBL2103838
Created by
admin on Mon Mar 31 18:07:03 GMT 2025 , Edited by admin on Mon Mar 31 18:07:03 GMT 2025
|
PRIMARY | |||
|
C96531
Created by
admin on Mon Mar 31 18:07:03 GMT 2025 , Edited by admin on Mon Mar 31 18:07:03 GMT 2025
|
PRIMARY | |||
|
10297982
Created by
admin on Mon Mar 31 18:07:03 GMT 2025 , Edited by admin on Mon Mar 31 18:07:03 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |